American Capital announced today it has committed $212 million in the One Stop Buyout of Cambridge Major Laboratories (CML), a global provider of complex chemistry-based outsourcing services to the pharmaceutical and biotechnology industries. CML expands American Capital's portfolio of healthcare products and services companies, which have aggregate revenues of over $600 million1. American Capital's investment took the form of debt and preferred and common equity. Jefferies & Company served as sole financial advisor to CML on the transaction. CML was a portfolio company of Arlington Capital Partners prior to American Capital's investment.

Based in Germantown, WI, CML is an active pharmaceutical ingredient (API) development and manufacturing organization serving a broad customer base of pharmaceutical, biotech and generic drug companies. The Company operates from FDA inspected facilities in the U.S. and Europe.

"CML has experienced substantial growth since inception due to the Company's continued expansion of its service offerings, operations and facilities," said Kyle Bradford , Principal, American Capital Buyouts Group. "As a result, CML is now a market leader across the entire spectrum of drug development and commercialization, providing services and products to customers with early-stage, late-stage and commercial compounds. The ompany's market position, complex chemistry abilities, outstanding execution of its service offerings and large state-of-the-art facilities, both in the U.S. and Europe, will allow CML to continue to meet the increased outsourcing demand from pharmaceutical and biotech companies. We look forward to working with CML's management team to substantially grow the Company, both organically and through acquisitions."

American Capital and its affiliated funds have invested approximately $31 billion in over 540 portfolio companies both directly and in support of leading financial partners in change of control transactions.